MedPath

Effects of CoSeal on Bleeding & Adhesions in Pediatric Heart Surgery

Phase 2
Completed
Conditions
Surgery-Induced Tissue Adhesions
Hemorrhage
Congenital Heart Defect
Interventions
Device: CoSeal Surgical Spray Group
Registration Number
NCT01330433
Lead Sponsor
Loma Linda University
Brief Summary

This is a prospective, randomized, open-label, blinded-evaluator study that will evaluate the effectiveness of a surgical sealant (CoSeal) composed of biocompatible polyethylene glycol on the formation of mediastinal and pericardial adhesions in children undergoing staged surgical reconstruction (potential procedures include: Blalock-Taussig Type Operation, Classical Glenn Procedure, Bidirectional Glenn Procedure, Norwood). Additionally, bleeding will be evaluated by drainage post-operatively through surgical site drainage output.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
35
Inclusion Criteria
  • Have an acceptable surrogate capable of giving consent on the subject's behalf.
  • Pediatric patients ages 0 - 17
  • Have a cardiac disease which requires staged cardiac surgery and resternotomy
  • Non-emergent state or emergent state with sufficient time to educate and consent
Exclusion Criteria
  • An immune system disorder
  • Unplanned reoperation
  • Known hypersensitivity to components in CoSeal
  • Patients undergoing reoperation less than 3 months after the primary surgery

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CoSeal Spray GroupCoSeal Surgical Spray GroupCoSeal Spray will be applied at the end of the first staged procedure in patients randomized to the experimental group.
Primary Outcome Measures
NameTimeMethod
Severity of Adhesions at the Retrosternal SiteSeverity of adhesions data will be collected during approximately the first 30-60 minutes of the second staged surgery

Severity of adhesions at seven predefined sites (pericardial or retrosternal, inferior or diaphragmatic region, right lateral or arterial region, region around great vessels). Severity of adhesions is graded as 0 = no adhesions, 1 = filmy and avascular, 2 = requiring blunt dissection, 3 = requiring sharp dissection, 4 = requiring extensive sharp dissection. Adhesion scores for each patient will be derived from the sum of adhesion severity scores at each site, from 0 (no adhesions) to 28 (cohesive adhesions at all sites).

Severity of Adhesions at the Diaphragm SiteSeverity of adhesions data will be collected during approximately the first 30-60 minutes of the second staged surgery

Severity of adhesions at five predefined sites (retrosternal, diaphragmatic region, right lateral, left lateral, arterial base). Severity of adhesions is graded as 0 = no adhesions, 1 = filmy and avascular, 2 = requiring blunt dissection, 3 = requiring sharp dissection, 4 = requiring extensive sharp dissection. Adhesion scores for each patient will be derived from the sum of adhesion severity scores at each site, from 0 (no adhesions) to 28 (cohesive adhesions at all sites).

Post-operative BleedingPost-operative bleeding data will be collected on average, during the first 36 hours after the surgery

Post-operative bleeding through surgical site drainage output.

Adhesion BurdenTime it takes for patient to be put on bypass (an average time between 0 and 120 minutes)

Skin to bypass time as an indicator of adhesion burden.

Severity of Adhesions at the Arterial Base Site.Severity of adhesions data will be collected during approximately the first 30-60 minutes of the second staged surgery

Severity of adhesions at five predefined sites (retrosternal, diaphragmatic region, right lateral, left lateral, arterial base). Severity of adhesions is graded as 0 = no adhesions, 1 = filmy and avascular, 2 = requiring blunt dissection, 3 = requiring sharp dissection, 4 = requiring extensive sharp dissection. Adhesion scores for each patient will be derived from the sum of adhesion severity scores at each site, from 0 (no adhesions) to 28 (cohesive adhesions at all sites).

Severity of Adhesions at the Left Lateral SiteSeverity of adhesions data will be collected during approximately the first 30-60 minutes of the second staged surgery

Severity of adhesions at five predefined sites (retrosternal, diaphragmatic region, right lateral, left lateral, arterial base). Severity of adhesions is graded as 0 = no adhesions, 1 = filmy and avascular, 2 = requiring blunt dissection, 3 = requiring sharp dissection, 4 = requiring extensive sharp dissection. Adhesion scores for each patient will be derived from the sum of adhesion severity scores at each site, from 0 (no adhesions) to 28 (cohesive adhesions at all sites).

Severity of Adhesions at the Right Lateral SiteSeverity of adhesions data will be collected during approximately the first 30-60 minutes of the second staged surgery

Severity of adhesions at five predefined sites (retrosternal, diaphragmatic region, right lateral, left lateral, arterial base). Severity of adhesions is graded as 0 = no adhesions, 1 = filmy and avascular, 2 = requiring blunt dissection, 3 = requiring sharp dissection, 4 = requiring extensive sharp dissection. Adhesion scores for each patient will be derived from the sum of adhesion severity scores at each site, from 0 (no adhesions) to 28 (cohesive adhesions at all sites).

Secondary Outcome Measures
NameTimeMethod
Hospital StayLength of stay after second surgery up to 1 month

Number of days post surgery.

Trial Locations

Locations (1)

Loma Linda University Medical Center

🇺🇸

Loma Linda, California, United States

© Copyright 2025. All Rights Reserved by MedPath